In vitro evaluation of B-domain deleted recombinant factor VIII (ReFacto®) stability during simulated continuous infusion administration

Haemophilia

Volumn 11, Issue 4, 2005, Pages 319-325

  Neidhardt, Edie ^a   Koval, R ^a   Burke, Elizabeth ^a,b   Warne, N ^a  

^a PFIZER INC   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Adsorption; Continuous infusion; Haemophilia A; In vitro stability; Recombinant factor VIII; Therapy

Indexed keywords

POLYVINYLCHLORIDE; RECOMBINANT BLOOD CLOTTING FACTOR 8; REFACTO AF CC;

ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DILUTION; DRUG ADSORPTION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EXPOSURE; DRUG STABILITY; DRUG STORAGE; ENVIRONMENTAL TEMPERATURE; IN VITRO STUDY; INFUSION PUMP; IONIC STRENGTH; PRIORITY JOURNAL; SIMULATION; TIME;

ADSORPTION; AMBULATORY CARE; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; HEMOPHILIA A; HUMANS; INFUSION PUMPS; POLYVINYL CHLORIDE; RECOMBINANT PROTEINS; SYRINGES;

EID: 22744431520     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01094.x     Document Type: Article

References (16)

1. Hay CRM, Doughty HI, Savidge GF. Continuous infusion of factor VIII for surgery and major bleeding. Blood Coagul Fibrinolysis 1996; 7(Suppl. 1): S15-9.
2. Martinowitz U, Schulman S. Coagulation factor concentrates by continuous infusion. Transfus Med Rev 1997; 11: 56-63.
3. Martinowitz UP, Schulman S. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Acta Haematol 1995; 94(Suppl. 1): 35-42.
4. Batorova A, Martinowitz U. Intermittent injection vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
5. Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous intermittent factor VIII concentrate therapy in hemophilia A. Am J Haematol 1984; 17: 85-8.
6. DiMichele DM, Lasak ME, Miller CH. In vitro factor VIII recovery during the delivery of ultra-pure factor VIII concentrate by continuous infusion. Am J Hematol 1996; 51: 99-103.
7. Österberg T, Fatouros A, Neidhardt E, Warne N, Mikaelsson M. B-domain deleted recombinant factor VIII formulation and stability. Semin Hematol 2001; 38: 40-3.
8. Juhlin F, Moberg U, Oswaldsson U, Renlund S, Mikaelsson M. Stability and Compatibility of Reconstituted Recombinant Factor VIII SQ (r-VIII SQ) in a System for Continuous Infusion [Abstract]. XXII International Congress of the World Federation of Haemophilia Meeting, Dublin, Ireland, June 23-28, 1996.
9. Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72: 403.
10. McMillan CW, Webster WP, Roberts HR, Blythe WB. Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol 1970; 18: 659-67.
11. Hathaway WE, Christian MJ, Clark SJ, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984; 17: 85-8.
12. Bona RD, Weinstein RE, Weisman SJ, Bartolomeo A, Rickles FR. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32: 8-13.
13. Martinowitz U. Stability of factor VIII preparation in continuous infusion. Ann Hematol 1994; 68: S69-71.
14. McLeod A, Walker S, Zheng S, Hayward C. Loss of factor VIII activity during storage in PVC containers due to adsorption. Haemophilia 2000; 6: 89-92.
15. Norde W. Adsorption of proteins from solution at the solid-liquid interface. Adv Colloid Interface Sci 1986; 25: 267-340.
16. Parti R, Ardosa J, Yang L, Mankarious S. In vitro stability of recombinant human factor VIII (Recombinate™). Haemophilia 2000; 6: 513-22.